Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Group letter to the Maryland Prescription Drug Affordability Board (PDAB) explaining the realities of treating chronic conditions and outlining why therapeutic alternatives are not always applicable to patients.
Group letter urging the Education & Workforce Committee to mark up the Safe Step Act in response to the ERISA 50th anniversary hearing.
CSC-led sign on letter to CMS providing feedback on CMS' Part C and Part D Medicare Prescription Payment Plan (M3P) model documents
Group letter to CMS commenting on the Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents.
Group letter to House and Senate leadership requesting a meeting with congressional offices to share patients perspectives and priorities re (1) improving and expanding access to high quality, affordable, insurance coverage, (2) reducing the burden of medical debt on patients, and (3) protecting patients by limiting junk insurance.
Group letter applauding newly released final rule on Section 1557 of the ACA that will strengthen non-discrimination protections in health care.
CSC letter to CMS commenting on the Medicare Prescription Payment Plan (M3P) Guidance Part Two. Comments focus on outreach, education, and communication requirements for Part D Sponsors; and pharmacy processes.
Group letter urging CMS to uphold the important protections under the 6PC policy as they implement the changes to the Part D program required under the IRA.
Group letter to CMS commenting on the Medicare Prescription Payment Plan (M3P) Draft 2 Guidance, recommending refinements to general outreach, education, and communication requirements for Part D sponsors, targeted outreach to patients likely to benefit, and election requirements.
Coalition letter to Ed & Workforce leadership commenting on the ERISA RFI, urging the committee to take action to reform step therapy and mark up the Safe Step Act (HR 2630)